Skip to content

Study · Non-randomized trial · 1992

4 results

Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay.

Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE

Thrombosis and haemostasis1 Jan 1992Cited by 49 (Europe PMC)

PMID1377412 (opens in a new tab)DOI10.1055/s-0038-1648390 (opens in a new tab)PepBankPUB-01377412
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialMechanism

    In volunteers, DDAVP produced a 6.6-fold increase in PAP complex, maximal 15 to 30 min after infusion began.

    In plain wordsIn volunteers, PAP complex increased after DDAVP infusion.

    Peptide
    Desmopressin
    Outcome
    IncreasePlasmin-alpha 2-antiplasmin complex increase
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Measurements

    PAP complex increase
    6.6 fold
    DDAVP
    Time to maximum
    15 to 30 min
    after infusion start

    Source sentences

    Summary
    Infusion of DDAVP in a randomized placebo controlled crossover study resulted in all volunteers in a 6.6-fold increase in PAP complex, which was maximal between 15 and 30 min after the start of the infusion.
    1 context sentence
    Summary · context
    The assay was validated in healthy volunteers and in patients with an activated fibrinolytic system.
  2. 02HumanNon-randomized trialMechanism

    In volunteers after DDAVP infusion, PAP complex levels decreased with an apparent disappearance half-life of about 120 min.

    In plain wordsIn volunteers after DDAVP infusion, PAP complex levels fell with an apparent half-life of about 120 minutes.

    Peptide
    Desmopressin
    Outcome
    DecreasePAP complex disappearance
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Measurements

    PAP complex disappearance half-life
    ≈ 120 min
    after DDAVP infusion

    Source sentences

    Summary
    Hereafter, plasma levels of PAP complex decreased with an apparent half-life of disappearance of about 120 min.
    2 context sentences
    Summary · context
    Infusion of DDAVP in a randomized placebo controlled crossover study resulted in all volunteers in a 6.6-fold increase in PAP complex, which was maximal between 15 and 30 min after the start of the infusion.
    Summary · context
    The assay was validated in healthy volunteers and in patients with an activated fibrinolytic system.
  3. 03HumanNon-randomized trialMechanism

    In volunteers, DDAVP did not induce thrombin generation measured by plasma prothrombin fragment F1+2.

    In plain wordsIn volunteers, DDAVP did not increase thrombin generation measured by prothrombin fragment F1+2.

    Peptide
    Desmopressin
    Outcome
    No significant changeProthrombin fragment F1+2
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    Infusion of DDAVP did not induce generation of thrombin, as measured by plasma levels of prothrombin fragment F1+2 and thrombin-antithrombin III (TAT) complex.
    1 context sentence
    Summary · context
    The assay was validated in healthy volunteers and in patients with an activated fibrinolytic system.
  4. 04HumanNon-randomized trialMechanism

    In volunteers, DDAVP did not induce thrombin generation measured by plasma thrombin-antithrombin III complex.

    In plain wordsIn volunteers, DDAVP did not increase thrombin generation measured by thrombin-antithrombin III complex.

    Peptide
    Desmopressin
    Outcome
    No significant changeThrombin-antithrombin III complex
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    Infusion of DDAVP did not induce generation of thrombin, as measured by plasma levels of prothrombin fragment F1+2 and thrombin-antithrombin III (TAT) complex.
    1 context sentence
    Summary · context
    The assay was validated in healthy volunteers and in patients with an activated fibrinolytic system.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.